Related Experiment Video

Updated: Sep 25, 2026

Screening Ion Channels in Cancer Cells
06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

The uPA/uPA receptor system as a target for tumor therapy

S Sperl1, M M Mueller, O G Wilhelm

  • 1Wilex AG, Munich, Germany.

Drug News & Perspectives
|June 19, 2003
PubMed

Insights

Targeting the urokinase-type plasminogen activator (uPA) system can inhibit tumor invasion and metastasis. Inhibiting uPA activity or its receptor binding shows therapeutic potential for drug development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Tumor invasiveness relies on proteolytic enzymes degrading the extracellular matrix.
  • The urokinase-type plasminogen activator (uPA) system is crucial for tumor cell invasion and metastasis.
  • This system comprises uPA, its receptor uPAR (CD87), and inhibitors PAI-1/PAI-2.

Purpose of the Study:

  • To explore the therapeutic relevance of targeting the uPA system in cancer.
  • To investigate strategies for inhibiting uPA enzymatic activity and/or uPAR binding.
  • To leverage structural information for drug design against uPA.

Main Methods:

  • Utilizing X-ray crystallography of uPA/inhibitor complexes to guide drug optimization.
  • Designing peptide compounds that mimic uPA epitopes to antagonize receptor binding.
  • Evaluating the potential of inhibiting uPA and uPAR interactions.

Main Results:

  • X-ray structures provide a basis for enhancing affinity and selectivity of uPA inhibitors.
  • Peptide-based antagonists effectively block the uPA-uPAR recognition process.
  • Both inhibition strategies show promise for therapeutic applications.

Conclusions:

  • Interference with the uPA system holds significant therapeutic potential for cancer treatment.
  • Structural insights facilitate the optimization of existing lead compounds for uPA inhibition.
  • Peptide mimetics offer a viable approach for designing drugs that target uPA-receptor interactions.

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...